Brad Hively sold $1.9M of STLN stock

Brad Hively, Dir of Starling Oncology, Inc. (STLN), sold 298,853 shares of STLN stock worth $1.9M, per an SEC Form 4 filed Aug 24, 2026.

The sale was pre-arranged (a 10b5-1 plan or an option exercise), not a fresh decision.

The trade happened on Aug 21, 2026, 3 days before it was made public.

STLN has moved -45.9% since the trade date, from $6.46 to $3.50 (Nov 13, 2026 close).